

Mariana P Socal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2135814/publications.pdf>

Version: 2024-02-01

34
papers

254
citations

1039406

9
h-index

1058022

14
g-index

34
all docs

34
docs citations

34
times ranked

236
citing authors

#	ARTICLE	IF	CITATIONS
1	The Pandemic and the Supply Chain: Gaps in Pharmaceutical Production and Distribution. American Journal of Public Health, 2021, 111, 635-639.	1.5	34
2	Using External Reference Pricing In Medicare Part D To Reduce Drug Price Differentials With Other Countries. Health Affairs, 2019, 38, 804-811.	2.5	21
3	Patient Selection After Mandatory Bundled Payments for Hip and Knee Replacement. Journal of Bone and Joint Surgery - Series A, 2020, 102, 325-331.	1.4	21
4	Occupational pesticide exposure and the risk of death in patients with Parkinson's disease: an observational study in southern Brazil. Environmental Health, 2020, 19, 68.	1.7	20
5	Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim. Value in Health, 2020, 23, 481-486.	0.1	19
6	Comparative Approaches to Drug Pricing. Annual Review of Public Health, 2020, 41, 499-512.	7.6	17
7	Favorable Formulary Placement of Branded Drugs in Medicare Prescription Drug Plans When Generics Are Available. JAMA Internal Medicine, 2019, 179, 832.	2.6	16
8	Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US. Pharmacoeconomics, 2020, 38, 1115-1121.	1.7	15
9	Judicialization 2.0: Understanding right-to-health litigation in real time. Global Public Health, 2019, 14, 190-199.	1.0	11
10	Changes Associated With the Entry of a Biosimilar in the Insulin Glargine Market. JAMA Internal Medicine, 2021, 181, 1405.	2.6	9
11	Barriers to biosimilar utilization in the United States. American Journal of Health-System Pharmacy, 2020, 77, 2006-2014.	0.5	8
12	Consumer Responses to Price Disclosure in Direct-to-Consumer Pharmaceutical Advertising. JAMA Internal Medicine, 2019, 179, 435.	2.6	7
13	Medicare Spending on Drugs With Accelerated Approval. Annals of Internal Medicine, 2022, 175, 938-944.	2.0	7
14	Branded prescription drug spending: a framework to evaluate policy options. Journal of Pharmaceutical Policy and Practice, 2017, 10, 31.	1.1	5
15	Parkinson's disease-associated dyskinesia in countries with low access to levodopa-sparing regimens. Movement Disorders, 2019, 34, 1929-1930.	2.2	5
16	Modifying the Criteria for Granting Orphan Drug Market Exclusivity. Value in Health, 2020, 23, 1470-1476.	0.1	5
17	Links Between Chronic Illness and Late-Life Cognition: Evidence From Four Latin American Countries. Journal of Aging and Health, 2018, 30, 262-304.	0.9	4
18	Naming Convention, Interchangeability, and Patient Interest in Biosimilars. Diabetes Spectrum, 2020, 33, 273-279.	0.4	4

#	ARTICLE	IF	CITATIONS
19	Misinformation in nutrition through the case of coconut oil: An online before-and-after study. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1375-1384.	1.1	4
20	Critical Drugs for Critical Care: Protecting the US Pharmaceutical Supply in a Time of Crisis. American Journal of Public Health, 2020, 110, 1346-1347.	1.5	3
21	Factors Associated With Prescriptions for Branded Medications in the Medicare Part D Program. JAMA Network Open, 2021, 4, e210483.	2.8	3
22	Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab. American Journal of Health-System Pharmacy, 2021, 78, 216-221.	0.5	3
23	Impacts of the 2017 Brazilian National Primary Care Policy on public primary health care in Rio de Janeiro, Brazil. Cadernos De Saude Publica, 2022, 38, .	0.4	3
24	Off-Label Coverage of High-Cost Drugs by Independent Charity Patient Assistance Programs. Journal of General Internal Medicine, 2021, 36, 555-556.	1.3	2
25	Right-to-Medicines Litigation and Universal Health Coverage: Institutional Determinants of the Judicialization of Health in Brazil. Health and Human Rights, 2020, 22, 221-235.	1.3	2
26	Trends of Prescription Drug Manufacturer Rebates in Commercial Health Insurance Plans, 2015-2019. JAMA Health Forum, 2022, 3, e220888.	1.0	2
27	Patient Narratives: a Tool for People-Centered Health Systems Education. Medical Science Educator, 2020, 30, 1437-1443.	0.7	1
28	The Role of Advance Purchasing Commitments in Government Drug Price Negotiations: Lessons From the COVID-19 Response. American Journal of Public Health, 2021, 111, 652-657.	1.5	1
29	Bipartisan Federal Legislation to Address Insulin Access and Affordability. Diabetes Spectrum, 2021, 34, ds210008.	0.4	1
30	Association Between Waste-Free Formularies and Prescription Drug Spending Among Self-insured Employers. JAMA Network Open, 2021, 4, e2131486.	2.8	1
31	Older Americansâ€™ Preferences Between Lower Drug Prices and Prescription Drug Plan Choice, 2019. American Journal of Public Health, 2020, 110, 354-356.	1.5	0
32	Reply to Comment on "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983â€“2017) and Associated Budget Impact in the US". Pharmacoeconomics, 2020, 38, 1375-1376.	1.7	0
33	Manufacturer-Sponsored Cost-Sharing Programs for Insulin: Are Patients Getting the Help They Need?. Journal of General Internal Medicine, 2021, , 1.	1.3	0
34	Measuring and Mitigating Gender-Based Disparities in Earning Potential in Academic Medicine. JAMA Network Open, 2022, 5, e220074.	2.8	0